Birkeland KI, Bodegard J, Banerjee A, et al. - This multinational observational cohort study was performed in patients with type 2 diabetes without a history of prevalent cardiovascular and renal disease (defined as cardiovascular and renal disease free) managed in routine clinical practice, to compare the risk of cardiorenal disease, heart failure (HF) or chronic kidney disease (CKD) in correlation with the new use of sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) vs dipeptidyl peptidase‐4 inhibitor (DPP4i). The participants were selected using electronic health records from England, Germany, Japan, Norway, South Korea and Sweden. Dapagliflozin and sitagliptin/linagliptin were the most frequently employed agents in the SGLT2i and DPP4i, groups, respectively. According to the findings, a lower risk of HF and CKD was observed in relation to treatment with SGLT2i vs DPP4i in patients with type 2 diabetes otherwise free from both cardiovascular and renal disease.